Advice

In the absence of a submission from the holder of the marketing authorisation.

bosentan (Traceleer®), is not recommended for use within NHS Scotland for the treatment of pulmonary arterial hypertension (PAH) WHO functional class II.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Download detailed advice24KB (PDF)

Download

Medicine details

Medicine name:
bosentan (Tracleer)
SMC ID:
523/08
Indication:
pulmonary arterial hypertension (PAH) WHO functional class II
Pharmaceutical company
Actelion Pharmaceuticals UK Ltd
BNF chapter
Cardiovascular system
Submission type
Non submission
Status
Not recommended
Date advice published:
10 November 2008